Taken all together, treatments with CKII inhibitor TBB, GSK3 inhibitors LiCl and AR, and Src/Fyn Kinase inhibitor Saracatinib showed robust inhibition leading to different reduced basal and OA-induced tau phosphorylation profiles demonstrating the specificity of inhibitors tested in our tauopathy cell-based models. The gene discussed is MAPT; the disease is tauopathy.